PLEASANTON, Calif., Oct. 15, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will host its investor day virtually on Thursday, November 7, 2024. The event will begin at 1:30 p.m. PT and will conclude at approximately 3:30 p.m. PT.
Veeva will broadcast the presentations live on the company's investor relations website, ir.veeva.com, where a link to the archived webcast will also be available after the event.
Event: Veeva Systems 2024 Investor Day
Date: Thursday, November 7, 2024
Time: 1:30 p.m. PT (4:30 p.m. ET)
Online event registration can be found on the company's investor relations website or directly at this link.
Webcast: ir.veeva.com
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva uses its ir.veeva.com website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor our investor relations website in addition to following our press releases, SEC filings, and public conference calls and webcasts.
Investor Relations Contact: | Media Contact: |
Gunnar Hansen | Maria Scurry |
Last Trade: | US$276.43 |
Daily Change: | -3.04 -1.09 |
Daily Volume: | 800,831 |
Market Cap: | US$45.310B |
September 02, 2025 August 28, 2025 August 27, 2025 August 18, 2025 July 23, 2025 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load